The Relationship of testosterone to prostate-specific antigen in men with sexual dysfunction

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 1, 2010, Pages 284-292

  Corona, Giovanni ^a,b   Boddi, Valentina ^a   Lotti, Francesco ^a   Gacci, Mauro ^a   Carini, Marco ^a   De Vita, Giulia ^a   Sforza, Alessandra ^b   Forti, Gianni ^a   Mannucci, Edoardo ^a   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BELLARIA HOSPITAL   (Italy)

Author keywords

Erectile dysfunction; Hypogonadism; Prostate; PSA; Testosterone; Testosterone deficiency syndrome

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE DERIVATIVE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; HELP SEEKING BEHAVIOR; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE DISEASE; RETROSPECTIVE STUDY; SYMPTOM; TESTOSTERONE BLOOD LEVEL;

EID: 74049096119     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01549.x     Document Type: Article

References (34)

1. Isaacs JT, Nieschlag E, Behre HM. Testosterone and the prostate. Testosterone: Action, deficiency, substitution 2004, 347-74. In, eds, 3rd, edition, Cambridge, Cambridge University Press
2. Morelli A, Corona G, Filippi S, Ambrosiani S, Forti G, Vignozzi L, Maggi M. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? Int J Endocrinol Invest 2007, 30:880-8.
3. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: Metabolic syndrome and erectile dysfunction. J Androl 2008, 30:10-22.
4. Kupelian V, Shabsigh R, Travison TG, Page ST, Araujo AB, McKinlay JB. Is there a relationship between sex hormones and erectile dysfunction? Results from the Massachusetts Male Aging Study. J Urol 2006, 176:2584-8.
5. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: Results of a meta-analysis. Clin Endocrinol (Oxf) 2005, 63:381-94.
6. Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008, 31:799-808.
7. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992, 75:1092-8.
8. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009, 6:1165-70.
9. Huggins C, Hodges CV. Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-7.
10. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008, 100:170-83. Endogenous Hormones and Prostate Cancer Collaborative Group
11. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006, 2:146-59.
12. Schroder FH, Roobol MJ. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol 2009, 19:227-31.
13. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2009, Jun 8. [Epub ahead of print]
14. Antunes AA, Srougi M, Dall'oglio MF, Vicentini F, Paranhos M, Freire GC. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening. J Sex Med 2008, 5:1702-7.
15. Behre HM, Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: Pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 1992, 75:1204-10.
16. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994, 40:341-9.
17. El-Sakka AI, Hassoba HM, Elbakry AM, Hassan HA. Prostatic specific antigen in patients with hypogonadism: Effect of testosterone replacement. J Sex Med 2005, 2:235-40.
18. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth. Eur Urol 2009, 55:310-21.
19. Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: Consensus report from the first National Institutes of Health international prostatitis collaborative network. Urology 1999, 54:229-33.
20. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004, 46:547-54.
21. Horwich A, Parker C. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007, 18(2):ii36-7. ESMO Guidelines Working Group, suppl
22. Corona G, Mannucci E, Petrone L, Fisher DA, Balercia G, Chiarini V, Maggi M. ANDROTEST: A structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med 2006, 3:706-15.
23. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006, 91:1995-2010.
24. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. J Clin Endocrinol Metab 2007, 92:405-13.
25. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 2008, Aug 30. [Epub ahead of print]
26. Morgentaler A, Bruning CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996, 276:1904-6.
27. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006, 68:1263-7.
28. Carroll P, Albertsen PC, Greene K, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A. Prostate-specific antigen best practice statement: 2009 update. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf, Copyright © 2009 American Urological Association Education and Research, Inc. Available at: (accessed August 2, 2009
29. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007, 13:5103-8.
30. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000, 49:1239-42.
31. Heinemann LA, Saad F, Heinemann K, Thai DM. Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency? Aging Male 2004, 7:211-8.
32. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000, 53:703-11.
33. Morley JE, Perry HM, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006, 53:424-9.
34. Corona G, Jannini EA, Maggi M. Inventories for male and female sexual dysfunctions. Int J Impot Res 2006, 18:236-50.